Pipeline
Project/ Compound |
Potential indication/ Disease area |
Submission status |
Milestones |
---|---|---|---|
GP2015 |
Arthritides (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), plaque psoriasis and others (same as reference product) | US: approved EU: submitted |
|
LA-EP2006 (pegfilgrastim) | Chemotherapy-induced neutropenia and others (same as reference product) | Phase III |
|
HX575 |
Chronic kidney disease, chemotherapy-induced anemia and others (same as reference product) | Phase III |
|
GP2013 (rituximab) | Follicular lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiites, and microscopic polyangiites (same as reference product) | US: Phase III EU: submitted |
|
GP2017 (adalimumab) | Arthritides (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), plaque psoriasis and others (same as reference product) | Phase III |
|
GP2018 (infliximab) | Autoimmune diseases including rheumatoid arthritis and psoriasis (same as reference product) | Phase I | |
GP1111 (infliximab) | Autoimmune diseases including rheumatoid arthritis and psoriasis (same as reference product) | Phase III |